Clinical trials: Vascular And Immunologic Diseases
Multiple Myeloma
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
After the KFDA (Korea Food and Drug Administration) approval of a new drug, an annual report of the drug's safety and efficacy data must be reported to the Health Authority in 6 years.
- Trial name
- NCT01005628
- Testing
- bortezomib
- Where
- South Korea
- Volunteers
- 1,121 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Rheumatoid Arthritis
Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance
Hypothesis: SLE and RA increase risk of myocardial infarction (MI, heart attack). Immune reactants in the circulation of SLE patients downregulate cholesterol efflux proteins 27-hydroxylase and ABCA1 and upregulate scavenger…
- Trial name
- NCT01180361
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Multiple Myeloma
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and…
- Trial name
- NCT04036461
- Testing
- CC-99712, BMS-986405
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Chronic Myeloproliferative Disorders, Leukemia
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
RATIONALE: Listening to relaxing music during a bone marrow biopsy may be effective in reducing anxiety and pain. PURPOSE: This randomized clinical trial is studying how well music works in reducing anxiety and pain in adult…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00376922
- Testing
- music therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Wake Forest University Health Sciences
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers.
- Conditions
- Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT05663502
- Testing
- Biospecimen Collection
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- AIDS Malignancy Consortium
Multiple Myeloma
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
- Trial name
- NCT06152575
- Testing
- Elranatamab, Elotuzumab, Pomalidomide
- Where
- 270 sites in United States, Argentina and 25 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma.
- Trial name
- NCT00097981
- Testing
- Thalidomide, Dexamethasone, DOXIL
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Polymyalgia Rheumatica, Giant Cell Arteritis
Polymyalgia Rheumatica and Giant Cell Arteritis
The purpose of this study is to delineate the association of the 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) detected vasculitis pattern of the large vessels (PET positivity) and the…
- Trial name
- NCT02985424
- Testing
- 18F-FDG PET/CT
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Svendborg Hospital
Plasma Cell Myeloma
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma.
- Trial name
- NCT03756896
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00060346
- Testing
- rituximab, cyclophosphamide, Doxorubicin
- Where
- 153 sites in United States
- Volunteers
- 16 people
- Sponsor
- Eastern Cooperative Oncology Group
Mucositis, Multiple Myeloma
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482846
- Testing
- Palifermin, melphalan, questionnaire administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment
Nowadays, more and more patients are receiving anticancer treatment by mouth and oral chemotherapy is a challenge for our health system as patients become autonomous and responsible for following their oral anti-cancer treatment…
- Trial name
- CPS MYELOME (NCT04309942)
- Testing
- Guided Clinical Pharmacy Consultation
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cholangiocarcinoma, Colorectal Cancer
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare…
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
- Trial name
- NCT06910670
- Testing
- Standard developed materials, Genetics Advisor Decision Aid
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma.
- Trial name
- FUSIONMM-003 (NCT02807454)
- Testing
- Daratumumab, Durvalumab, Pomalidomide
- Where
- 64 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Celgene
Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05372354
- Testing
- CC-92480, Tazemetostat, BMS-986158
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome
- Trial name
- ET-902-AID01 (NCT07212322)
- Testing
- CD19 UCAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cryopyrin Associated Periodic Syndrome
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.
- Trial name
- NCT05186051
- Testing
- ZYIL1 capsule
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Zydus Lifesciences Limited
Coronary Artery Disease, Hiv
How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: a Serial CT Study
Combined antiretroviral therapy (cART) is thought to promote coronary artery disease via a number of mechanisms: abnormal lipid profiles, endothelial dysfunction, hypertension, insulin resistance and renal impairment are the main…
- Trial name
- HART CT (NCT03986697)
- Testing
- Biktarvy
- Where
- United Kingdom
- Sponsor
- University of Liverpool
Alcoholism, HIV Infection
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
We propose to test, by DNA linkage analysis of family pedigree members, the following interrelated hypotheses: 1) that sexual orientation is genetically influenced; 2) that the development of Kaposi's sarcoma and other outcomes…
- Conditions
- Alcoholism, HIV Infection, Homosexuality, Kaposi's Sarcoma
- Trial name
- NCT00001294
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.